PRODUCTS

Products Coming Soon

Injectables*

diITIAZem

Therapeutic Class: .
Container:

125 mg dilTlAZem HCI
in 0.7%Sodium Chloride Injection 125 mL (1 mg/mL)
STRENGTH: 125 mg per 125 mL
NDC #: 70324-976-01
CONTAINER TYPE: 125 mL Conventional IV bag
EXPECTED LAUNCH: Q3 2019
125 mg dilTlAZem HCI
in 5% Dextrose Injection 125 mL (1 mg/mL)
STRENGTH: 125 mg per 125 mL
NDC #: 70324-951-01
CONTAINER TYPE: 125 mL Conventional IV bag
EXPECTED LAUNCH: Q3 2019

diITIAZem

EPINEPHrine

Therapeutic Class: .
Container:

2 mg EPINEPHrine HCI
in 0.9% Sodium Chloride Injection 250 mL (8 mcg/mL)
STRENGTH: 2 mg per 250 mL
NDC #: 70324-027-01
CONTAINER TYPE: 250 mL Blow-Fill-Seal (BFS) IV bag
EXPECTED LAUNCH: Q4 2019
5 mg EPINEPHrine HCI
in 0.9% Sodium Chloride Injection 250 mL (20 mcg/mL)
STRENGTH: 5 mg per 250 mL 
NDC #: 70324-052-01
CONTAINER TYPE: 250 mL BFS IV bag 
EXPECTED LAUNCH: Q4 2019
8 mg EPINEPHrine HCI
in 0.9% Sodium Chloride Injection 250 mL (32 mcg/mL)
STRENGTH: 8 mg per 250 mL 
NDC #: 70324-077-01
CONTAINER TYPE: 250 mL BFS IV bag 
EXPECTED LAUNCH: Q4 2019
EPINEPHrine

NOREPINEPHRINE

Therapeutic Class: .
Container:
4 mg NOREPINEPHrine HCI
in 5% Dextrose Injection 250 mL (16 mcg/mL)
STRENGTH: 4 mg per 250 mL 
NDC #: 70324-451-01
CONTAINER TYPE: 250 mL BFS IV bag 
EXPECTED LAUNCH: Q3 2019
8 mg NOREPINEPHrine HCI
in 5Dextrose Injection 250 mL (32 mcg/mL)
STRENGTH: 8 mg per 250 mL 
NDC #: 70324-476-01
CONTAINER TYPE: 250 mL BFS IV bag 
EXPECTED LAUNCH: Q3 2019
16 mg NOREPINEPHrine HCI
in 5Dextrose Injection 250 mL (64 mcg/mL)
STRENGTH: 16 mg per 250 mL 
NDC #: 70324-002-01
CONTAINER TYPE: 250 mL BFS IV bag 
EXPECTED LAUNCH: Q4 2019
NOREPINEPHRINE
PLEASE CHECK BACK OFTEN AS OUR PORTFOLIO OF PRODUCTS IS CONSTANTLY EXPANDING!